Publishing date: October 2012
Author(s): Viswanathan D, Goldberg I, Graham SL
Australian School of Advanced Medicine, Macquarie University, Sydney, Australia.
BACKGROUND: To determine the change in central corneal thickness (CCT) over time and whether use of long term topical antiglaucoma medications influences CCT.
DESIGN: Case control study with retrospective and prospective data collection
PARTICIPANTS: 187 eyes of 187 glaucoma patients (mean follow up 6.92 ± 1.67 years) being treated with topical antiglaucoma medications (at least 3 years) with no history of surgery or laser were included and compared with 100 eyes of 100 age matched untreated control subjects (mean follow up 6.58 ± 1.93 years) who were glaucoma suspects with normal intraocular pressure (IOP) not on any treatment.
METHODS: Demographic data, CCT and IOP were collected at initial glaucoma diagnosis and at most recent visit and findings were compared between two groups.
MAIN OUTCOME MEASURES: Mean change in CCT in microns (μm)
RESULTS: CCT fell significantly (p < 0.0001) in treated eyes but not in control eyes (p = 0.18) , mean CCT reduction was 12.29 ± 13.65 μm in treated eyes and 1.17 ± 8.75 μm in controls. Amongst treated eyes, CCT reduction was significant (p < 0.0001) in those treated with either prostaglandins or a combination of prostaglandin and betablockers, while no significant reduction occurred in eyes treated with only betablockers ( p = 0.15) when compared with control eyes.
CONCLUSIONS: Prostaglandins appear to be associated with a small but significant CCT reduction over time. Serial CCT measurements might be helpful in glaucoma patients, particularly those on prostaglandins.
© 2012 The Author. Clinical and Experimental Ophthalmology
© 2012 Royal Australian and New Zealand College of Ophthalmologists.
Clin Experiment Ophthalmol. 2012 Sep 7. doi: 10.1111/j.1442-9071.2012.02870.x.
Clinical Paper of the Month manager: Andreas Boehm